UC Irvine
UC Irvine Previously Published Works

Title

Potassium channel subunits encoded by the KCNE gene family: physiology and pathophysiology of the MinK-related peptides (MiRPs).

Permalink

https://escholarship.org/uc/item/5cr1g4k3

Journal

Molecular interventions, 1(2)

ISSN

1534-0384

Authors

Abbott, GW
Goldstein, SA

Publication Date

2001-06-01

Copyright Information

Peer reviewed

Potassium Channel Subunits Encoded by the *KCNE* Gene Family:

Physiology and Pathophysiology of the MinK-Related Peptides (MiRPs)

The electrocardiogram shown above demonstrates an arrhythmia, called torsades de pointes (sinusoidal trace at right), that is incompatible with the normal pump function of the heart. This particular case was drug-induced and reflects the impairment of specific potassium channels that normally promote the repolarization phase of the cardiac action potential. New insights into the mutations and drugs that compromise the cellular flux of potassium, not only in the heart but also in other organs, are being gained through investigations of the protein components of voltage-gated potassium channels.

Voltage-gated potassium channels provide tightly controlled, ion-specific pathways across membranes and are key to the normal function of nerves and muscles. They arise from the assembly of four pore-forming proteins called α-subunits. To attain the properties of native currents, α-subunits interact with additional molecules such as the MinK-related peptides (MiRPs), single-transmembrane subunits encoded by the *KCNE* genes. Significantly, mutations in *KCNE 1, 2,* and *3* have been linked either to life-threatening cardiac arrhythmia or a disorder of skeletal muscle, familial periodic paralysis. The capacity of MiRPs to partner with multiple α-subunits in experimental cells appears to reflect still undiscovered roles for the *KCNE*-encoded peptides in vivo. Here, we consider these unique peptides in health and disease, and discuss future research directions.

■ *Geoffrey W. Abbott and Steve A. N. Goldstein*
Departments of Pediatrics and Cellular and Molecular Physiology
Boyer Center for Molecular Medicine
Yale University School of Medicine
New Haven, CT 06536

Review

INTRODUCTION

Potassium channels regulate fluid homeostasis, signaling in nervous tissue, and muscular contraction. This array of tasks is achieved by the controlled and exquisitely timed opening and closing of the water-filled channels through which potassium ions diffuse across cell membranes (1). For example, in the heart, voltage-gated potassium (VGK) channels open in response to a depolarizing wave of excitation that travels through the cells with each beat. The resulting efflux of potassium ions repolarizes the cells, thereby closing the channels and ending the excitation–contraction cycle so that the muscle is prepared to beat again. Similarly, VGK channels in nerve cells facilitate rapid signal transmission and limit excitatory influences. These crucial functions explain why drugs that act on potassium channels, and mutations in channel genes, can have significant effects on human physiology (2).

As shown in Figure 1, each of the four pore-forming α-subunits of VGK channels has six transmembrane (TM) segments and a single pore (P) loop that includes the signature sequence TXG$^Y/_F$G (3). The tetrameric assemblies form a single, central, ion-selective pore that is lined by the four P loops and the TM segments flanking each P loop in the primary structure (identified as S5 and S6) (4–5). The fourth TM segment of each α-subunit (S4) contains periodic basic residues and acts as the voltage sensor (6–7). In general, the expression of an α-subunit subtype (e.g., KCNQ1, HERG, or Kv3.4) gives rise to functional channels in experimental cells such as *Xenopus laevis* oocytes or mammalian tissue cells in culture. The currents that arise from these α-subunits, however, are often unlike the native currents manifested by cells in which they are naturally expressed. One well-known explanation for this disparity is the requirement for additional (sometimes called "accessory" or β) subunits—some cytoplasmic, others that are integral to the membrane—that modulate channel properties (8).


Figure 1. The *KCNE* genes encode single-transmembrane–domain peptides (i.e., MiRPs) that regulate voltage-gated potassium (VGK) channels. VGK channels are formed by association of four α-subunits (blue). Each α-subunit contains six transmembrane domains and one pore-forming P loop (P; see inset). P loops contain the pentapeptide sequence TXG$^Y/_F$G at the ion selectivity filter portion of the pore. In cells, potassium channel α-subunits interact with additional subunits, such as MiRPs (red), as well as membrane and cytosolic regulators (not shown). The MiRPs are encoded by *KCNE* genes and are a family of β-subunits that assemble (denoted by arrow) with α-subunits to generate native channels. The stoichiometry of MiRP subunits within each channel is not known; a possible $\alpha_4\beta_2$ complex is shown (looking down onto the plane of the exterior membrane surface; right), suggesting close approximation of MiRP and the ion conduction pore (17, 73).

The additionally required subunits that we describe here are encoded by the *KCNE* gene family and consist of 103 to 177 residues, with a single TM domain. These peptides associate with α-subunits to form stable assemblies with unique properties (Figure 1). The family of peptides encoded by the *KCNE* genes has five known members, three of which have been characterized. The founding member, MinK, is encoded by *KCNE1* and was discovered in 1988 by functional expression of fractionated rat kidney RNA *(9)*. A decade later, *KCNE2*, *KCNE3*, and *KCNE4* were discovered by focusing on motifs in MinK critical to function using homology-based searches of expressed sequence tag databases; the corresponding gene products were designated the MinK-Related Peptides (MiRPs) 1, 2, and 3 (Figure 2) *(8–10)*. *KCNE5*, encoding MiRP4, was subsequently found in a gene-rich segment of DNA, the deletion of which results in a syndrome denoted as AMME (for Alport syndrome, mental retardation, midface hypoplasia, and elliptocytosis) *(11)*. MinK has been shown to function in the heart and ear *(2)*, MiRP1 in the heart *(10, 12)*, and MiRP2 in

skeletal muscle *(13)*, whereas roles for MiRP3 and MiRP4 are not yet described.

MinK, MiRP1, and MiRP2 contribute to the function of VGK channels by influencing channel gating (i.e., channel opening and closing), ion selectivity, and ion flux rate (single channel conductance); they also significantly affect the pharmacology, regulation, and surface expression of VGK channels *(10, 12–18)*. Indeed, concurrent expression of MiRPs and α-subunits (e.g., MinK/KCNQ1, MiRP1/HERG, and MiRP2/Kv3.4) in experimental systems recapitulates the properties of native currents *(10, 13, 14)*, and mutations in *KCNE1*, *KCNE2*, and *KCNE3* are associated with inherited and acquired disease *(10, 12, 13, 19–21)*. Here, we consider the influence of MinK, MiRP1, and MiRP2 in native potassium channels. Other current reviews have addressed the issues of MinK tissue distribution and regulation *(22, 23)*, structure–function relationships in MinK/KCNQ1 and MiRP1/HERG complexes *(8)*, and the controversial issue of whether the MiRPs act through close juxtaposition with the channel ion conduction pore *(24, 25)*.

Potassium currents of four types contribute to the cardiac action potential: transient outward (I_{to}), leak (I_{Kp}), delayed rectifiers (I_{Kr} and I_{Ks}), and inward rectifier (I_{Kir}); see *(32, 33)*. Calcium and sodium channels are key to phase 0 depolarization (i.e., a positive shift in the cell voltage from resting membrane potential). I_{to} currents are activated by this depolarization to produce phase 1 repolarization, a partial return toward resting potential as potassium leaves the cell through channels, putatively formed by Kv1.4, Kv4.2 and/or Kv4.3 subunits, that inactivate rapidly. The plateau of the action potential (phase 2) is maintained by calcium and potassium currents (variously called I_{Kp}, I_{Ksus}, or I_{Kur}) that appear to be carried by Kv1.5 and/or KCNK-type 2–P-domain leak channels *(34)*. I_{Kr} and I_{Ks}, the delayed rectifiers, are

Figure: Potassium currents in the cardiac action potential.

activated more slowly upon depolarization and return cells to rest during phase 3 repolarization; I_{Kr} and I_{Ks} appear to be carried by MiRP1/HERG and MinK/KCNQ1 channels, respectively, as we discuss here. The rise from rest to threshold (phase 4) determines heart rate and is mediated by inwardly rectifying potassium currents (I_{Kir}) including I_{K1} (generated by K_{ir}2.1-4 subunits), I_{KAch} (attributed to K_{ir}3.1 and K_{ir}3.4 subunits) and I_{KATP} (arising from K_{ir}6.1 and SUR subunits) as well as a non-selective cation current (I_F) formed of HCN family subunits.

The majority of mutations and polymorphisms that have been associated with arrhythmia occur in genes for the delayed rectifier channels I_{Kr} and I_{Ks}. In these cases, arrhythmia results from reduction of potassium flux, impairing repolarization capacity, and prolonging the cardiac action potential (see dashed line in Figure). This prolongation is reflected on the surface electrocardiogram as a long QT interval and predisposes patients to torsades de pointes* (TdP), ventricular fibrillation (VF), and sudden death *(35–37)*. Reduced flux can result from channels with suboptimal gating kinetics (e.g., slow rates of opening or passing ions, or increased rates of closing, perhaps effected by drugs); reduced flux can alternatively result from a reduced number of channels in the plasma membrane. Of the six loci that have been associated with long QT intervals, two have been identified as *KCNE* genes (*KCNE1* and *KCNE2*); two others have been ascribed to genes for the respective α-subunit partners (*KCNQ1* and *HERG*); one is linked to a sodium channel gene (*SCN5A*); and the final locus has not been correlated to a specific gene *(38)*. ♥

---

*Torsades de pointes: a ventricular tachycardia characterized by fluctuation of QRS complexes around the electrocardiographic baseline.

Review


```
KCNE1 (MinK)   ---------- ------MILS NTTAVTPFLT KLWQETVQQG GNMSGLARRS PRSSDGKLEA LYVLMVLGFF GFFTLGIMLS YIRSKKLEHS NDPFNVYIES
KCNE2 (MiRP1)  ---------- MSTLSNFTQT LEDVFRRIFI TYMDNWRQNT TAEQEALQAK VDAENFYYVI LYLMVMIGMF SFIIVAILVS TVKSKRREHS NDPYHQYIVE
KCNE3 (MiRP2)  --METTNGTE TWYESLHAVL KALNATLHSN LLCRPGPGLG PDNQTEERRA SLPGRDDNSY MYILFVMFLF AVTVGSLILG YTRSRKVDKR SDPYHVYIKN
KCNE4 (MiRP3)  ---------- ---------- ----MLKMEP LNSTHPGTAA SSSPLESRAA GGGSGNGNEY FYILVVMSFY GIFLIGIMLG YMKSKRREKK SSLLLLYKDE
KCNE5 (MiRP4)  MNCSESQRLR TLLSRLLLEL HHRGNASGLG AGPRPSMGMG VVPDPFVGRE VTSAKGDDAY LYILLIMIFY ACLAGGLILA YTRSRKLVEA KDEPSQACAE


KCNE1 (MinK)   DAWQEKDKAY VQARVLESYR SCYVVENHLA IEQPNTHLPE TKPSP
KCNE2 (MiRP1)  DWQEKYKSQI LNLEESKATI HENIGAAGFK MSP
KCNE3 (MiRP2)  RVSMI
KCNE4 (MiRP3)  ERLWGEAMKP LPVVSGLRSV QVPLMLNMLQ ESVAPALSCT LCSMEGDSVS SESSSPDVHL TIQEEGADDE LEETSETPLN ESSEGSSENI HQNS
KCNE5 (MiRP4)  HEWAPGGALT ADAEAAAGSQ AEGRRQLASE GLPALAQGAE RV
```

Figure 2. Alignment of amino acid sequences encoded by human *KCNE1, 2, 3, 4,* and *5*. Predicted transmembrane domains are highlighted blue, and highly conserved residues are highlighted yellow. Protein products are named in parentheses next to the respective genes.

MinK, THE *KCNE1* GENE PRODUCT

When mRNA that encodes rat MinK is injected into *Xenopus laevis* oocytes, a very slowly activating potassium current is observed that is similar (but not identical) to the cardiac delayed rectifier current I_{Ks} *(9, 26)*. That this 130-residue peptide appeared to form channels on its own produced a controversy only later laid to rest by the cloning of its pore-forming partner, KCNQ1. Specifically, the *KCNQ1* gene (originally *KvLQT1*; first isolated by its linkage to the cardiac rhythm disorder known as long QT syndrome) was recognized to encode a classical VGK α-subunit *(27)*. The paired expression of *KCNQ1* with *KCNE1* in experimental cells thus reproduced currents that resembled the native I_{Ks} of cardiac myocytes *(14, 74)*. MinK-induced currents in oocytes are thus attributable to a *Xenopus laevis* ortholog of KCNQ1 *(14)*. Indeed, MinK does not generate currents in cells, such as Chinese hamster

ovary (CHO) cells, that lack endogenous KCNQ1 *(28)*. In addition to contributing to the formation of I_{Ks} channels with KCNQ1, MinK may also influence the function of HERG (see section on MiRP promiscuity, below) *(39)*.

The most apparent effect of MinK on KCNQ1 is an approximately tenfold slowing of activation kinetics (Figure 3), although MinK also alters inactivation and deactivation gating *(17, 29)*. Moreover, the unitary conductance of the MinK/KCNQ1 channels (in symmetric 140 mM potassium ions) is approximately fourfold greater than that of homomeric KCNQ1 channels *(17, 30)*. MinK also alters selectivity for monovalent cations *(16, 17)*, sensitivity to both external and internal pore blockers *(18, 31)*, inhibition by class III anti-arrhythmic agents (i.e., potassium channel blockers) *(15)*, and activation by small-molecule regulators *(15)*.

Inheritance of single missense mutations in *KCNE1* leading to

Figure 3. MinK associates with KCNQ1 to generate I_{Ks}. The human gene for the α-subunit KCNQ1 can be expressed (here in *Xenopus laevis* oocytes in whole-cell mode) to generate functional VGK channels (left). Co-expression of MinK is required, however, to generate a current that is like I_{Ks} in cardiac myocytes (right). Note that MinK greatly augments KCNQ1-mediated currents, and retards current activation. Cells were held at -80 mV and depolarized for 5 s to voltages of -60 (red), -40 (green), -20 (yellow), 0 (purple), 20 (orange), 40 (blue), and 60 (pink) mV.

A

B

Figure 4. Inherited mutations in the MinK-encoding gene *KCNE1* compromise VGK currents and are associated with arrhythmia.
A. Schematic of the MinK peptide indicating disease-associated mutations. Residues highlighted in red represent missense mutations (i.e., S74L and D76N) that have been functionally characterized and clinically associated with arrhythmia (see text for details; also see panel **B**); residues highlighted in yellow represent mutations that occur in individuals with arrhythmia but that have not been functionally characterized (*CHO*, predicted sites of glycosylation; *P*, predicted sites of phosphorylation).
B. Characterization of I_{Ks} current arising from mutant MinK. Currents were studied in *Xenopus laevis* oocytes and measured in excised inside-out patches in symmetrical 100 mM KCl. The KCNQ1 protein was co-expressed either with wild-type MinK or mutant form of MinK that is associated with Jervell and Lange-Nielsen syndrome. Patches were held at -60 mV and depolarized for 6 s to voltages of 0 (red), 20 (green), 40 (yellow), 60 (purple), and 80 (orange) mV. (NB: The reduction in single channel conductance associated with the mutant MinK is not indicated; see text for details.)

the replacement of serine at position 74 with leucine, or aspartate at position 76 with asparagine (Figure 4A) has been associated with inherited long QT syndrome *(17, 19–21, 40)*. Mutations in *KCNE1* reduce net potassium flux by producing a positive shift in the voltage dependence of activation (i.e., less current is generated at a given level of depolarization), a reduction in the single channel conductance, and accelerated deactivation (Figure 4B) *(17)*. Mutations in *KCNE1* (and *KCNQ1*) have been implicated also in predisposition to drug-induced long QT syndrome *(50, 51)*.

Individuals who carry two mutant alleles of *KCNE1* can suffer from a prolonged QT interval combined with sensorineural deafness (i.e., Jervell and Lange-Nielsen syndrome; JLNS) *(21, 40)*. Congenital deafness in these cases stems from disrupted production of endolymph due to defective I_{Ks} channels in the stria vascularis in the cochlea *(41)*. Thus, a point mutation in *KCNE1* has pathological consequences in multiple tissues, indicative of a channel complex with multiple roles. It should be noted that *KCNE1* transcripts are found in heart, auditory epithelium, kidney,

eye, gastrointestinal tract, and T cells *(22, 23)*.

MiRP1, THE *KCNE2* GENE PRODUCT

Even as HERG was becoming recognized as the likely molecular correlate for I_{Kr} based on transcript levels and function, its failure to fully recapitulate native I_{Kr} currents on its own led to the suggestion that an additional subunit might be required *(43)*. Study of *KCNE2* resolved the disparity between native and cloned (i.e., homomeric) HERG channels; MiRP1 and HERG were found to form stable complexes that behave like native I_{Kr} channels (Figure 5) in terms of their unitary conductance, sensitivity to external potassium ions, deactivation rate and, notably, inhibition by the anti-arrhythmic agent E-4031; thus, homomeric HERG channels were inhibited by E-4031 only in a use-dependent fashion during repetitive pulse cycles, whereas MiRP1/HERG and native I_{Kr} channels show tonic block (prior to the first activating pulse) and ready relaxation to equilibrium blockade. Although

Figure 5. MiRP1 associates with HERG to generate I$_{Kr}$. The human gene for the α-subunit HERG can be expressed (here in *Xenopus laevis* oocytes in whole-cell mode) to generate functional VGK channels. Co-expression of MiRP1 is required, however, to generate a current that is typical of I$_{Kr}$ in cardiac myocytes. Note that MiRP1 greatly decreases HERG-mediated currents and accelerates channel deactivation. Cells were held at -80 mV and depolarized for 3 s to voltages of -60 (red), -40 (green), -20 (yellow), 0 (purple), 20 (orange), and 40 (blue) mV, and were subsequently repolarized to −100 mV.

unitary conductance and gating kinetics were altered by MiRP1, the distinctive gating attributes of HERG-containing channels were qualitatively unchanged: With depolarization, the channels activate but generate little outward current due to rapid inactivation; upon repolarization, transition to the closed state is slow, allowing for further ion flux *(42)*.

Consistent with a role in repolarization of the myocardium, mutations that impair MiRP1 function are associated with inherited cardiac arrhythmia *(10)*. Four mutations in *KCNE2* have been found that correlate to a prolonged QT interval and/or TdP (Figure 6): the Q9E substitution (glutamine to glutamate at position 9) within the predicted extracellular portion of MiRP1; M54T (methionine to threonine) and I57T (isoleucine to threonine) substitutions in the predicted TM domain; and A116V (alanine to valine) in the predicted cytoplasmic domain. All four mutations diminish baseline potassium flux through the MiRP1/HERG channels: the Q9E substitution shifts the voltage dependence of activation to more positive values; the M54T substitution accelerates channel deactivation; and the I57T and A116V substitutions apparently compromise unitary current magnitude and cell surface half-life, respectively (F. Sesti, personal communication).

Although inherited arrhythmia is rare, acquired arrhythmia is relatively common in association with adverse reactions to medications, drugs of abuse, and metabolic abnormalities. As is true of most common disorders, acquired long QT syndrome appears to have a multifactorial basis. Thus, patients often present with multiple inciting factors (e.g., hypokalemia and female sex) that act cumulatively to impede cardiac repolarization *(37, 44)*. Of particular clinical relevance is the increased likelihood that individuals with a prolonged QT interval may develop arrhythmia in response to drug intake *(45, 46)*. Thus, individuals harboring

Figure 6. Mutations of the MiRP1-encoding gene *KCNE2* can severely compromise VGK currents and are associated with arrhythmia. The schematic of MiRP1 indicates disease-associated mutations. Residues highlighted in red represent missense mutations (i.e., Q9E, M54T, I57T, and A116V) that have been functionally characterized and clinically associated with arrhythmia (see text for details); the residue highlighted in blue represents the site of a polymorphism (i.e., T8A) associated with drug-induced arrhythmia (*CHO*, predicted sites of glycosylation; *P*, predicted sites of phosphorylation).

**Figure 7. Schematic of the MiRP2 peptide indicating a mutation associated with familial periodic paralysis.** The residue highlighted in red represents a missense mutation (i.e., R83H) that is associated with disease (*CHO*, predicted sites of glycosylation; *P*, predicted sites of phosphorylation).

the M54T, I57T, and A116V variants of MiRP1 came to clinical attention when they ingested procainamide, oxatomide, and quinidine, respectively, three agents that inhibit I_{Kr} channels and delay myocardial repolarization *(12)*. In these cases, the corresponding *KCNE2* mutations do not alter sensitivity of the channel to the given drug. Conversely, the Q9E variant of MiRP1, identified in a patient with a long QT interval at baseline in whom clarithromycin had induced TdP and VF, not only affects channel gating to reduce potassium flux, but increases sensitivity of MiRP1/HERG channels to inhibition by the drug *(10)*, a macrolide antibiotic previously associated with long QT syndrome and I_{Kr} blockade *(47)*. The patient, moreover, was female and hypokalemic when she developed arrhythmia, two other factors associated with reduced I_{Kr} current density. The consequences of *KCNE2* mutations thus underscore the need to consider acquired long QT syndrome in multifactorial terms.

In contrast to the patients characterized by rare (less than 0.02 percent of the general population) mutations of channel genes such as *KCNE2*, many more individuals appear free of an "inherent" risk of arrhythmia (i.e., their electrocardiogram is normal) but are nevertheless prone to acquire arrhythmia in response to certain drugs. In particular, the T8A polymorphism of MiRP1 is present in ~1.6 percent of the general population, and although it is associated with neither inherited long QT syndrome nor changes in MiRP1/HERG channel function *(10)*, the variant increases sensitivity to blockade by a common antibiotic (leading to 50% current suppression at levels of the drug present in serum) and is implicated in drug-induced arrhythmia *(12)*. Thus, a common polymorphism can carry important clinical implications for choice of drug therapy where alternatives exist, as well as for future drug development.

Because I_{Kr} channels appear to be particularly susceptible to blockade by a range of drugs, including anti-arrhythmic agents, antibiotics, antihistamines, and psychotropic drugs *(48)*, it has

been proposed that several unique structural features of HERG make it prone to drug blockade. These include a large internal channel cavity bearing aromatic residues that may facilitate binding and trapping of small molecules *(49)*. The structural characteristics of MiRP1 that contribute to the susceptibility of I_{Kr} to drug blockade have not yet been elaborated.

MiRP2, THE *KCNE3* GENE PRODUCT

MiRP2 is only 103 residues long, with a short predicted intracellular domain (Figure 7) *(8, 10, 13)*. In contrast to *KCNE1* and *KCNE2*, transcripts of the *KCNE3* gene (encoding MiRP2) are most abundant in skeletal, rather than cardiac, muscle. The search for a pore-forming α-subunit that might partner with MiRP2 to form native potassium currents led to Kv3.4, a VGK channel protein prominent in skeletal muscle. Kv3.4 was found to be coordinately expressed with MiRP2 in rat sartorius and murine C2C12 cell plasma membranes and to form stable assemblies with MiRP2 that altered the biophysical and pharmacological properties of Kv3.4 to match those of a native muscle channel *(13)*.

Related to the Drosophila *Shaw* family of potassium channels, homomeric Kv3.4 channels activate at supra-threshold potentials and inactivate rapidly (i.e., A-type behavior). These properties, however, are not observed in skeletal muscle, although Kv3.4 protein is conspicuous. Dependence of the native current on association with MiRP2 seems to explain this finding, at least in part, as MiRP2/Kv3.4 channels activate at sub-threshold potentials (with a midpoint voltage dependence ~45 mV more negative than homomeric Kv3.4 channels), and like native channels in C2C12 skeletal muscle cells, their steady-state activity at negative voltages is ~80-fold greater than channels that lack MiRP2 (Figure 8) *(13)*. MiRP2 also decreases channel sensitivity to the sea anemone toxin BDS-II, producing an inhibition constant similar to that manifested by native channels in muscle cells, and endows Kv3.4 subunits with a single channel conductance and rate of recovery from inactivation typical for native channels *(13)*.

The observed effects of MiRP2 alter our expectations for the role for Kv3.4 subunits in skeletal muscle physiology. Previously, Kv3.4 channels were hypothesized to modulate calcium currents (owing to their supra-threshold activation) and to produce afterhyperpolarization (due to slow recovery from inactivation), thereby limiting action potential frequency *(52)*. In contrast, MiRP2/Kv3.4 channels activate at sub-threshold potentials and, thereby, contribute to the skeletal muscle resting membrane potential *(13)*. Moreover, their rapid recovery from inactivation suppresses afterhyperpolarization and minimizes cumulative inactivation to facilitate rapid trains of action potentials (Figure 9).

As in the case of *KCNE1* (MinK) and *KCNE2* (MiRP1), mutation of the *KCNE3* gene has been associated with compromised muscle function. The familial periodic paralyses are disorders of skeletal muscle that had previously been associated with mutations

Figure 8. The *KCNE3*-encoded peptide MiRP2 associates with the α-subunit Kv3.4 to generate VGK channel currents typical of skeletal myocytes.
A. The human gene for the α-subunit Kv3.4 can be expressed in CHO cells to generate functional VGK channels. Co-expression of MiRP2 is required, however, to generate a current that is typical of skeletal myocytes (right); note that MiRP2 leads to sub-threshold currents. Cells were held at -80 mV and depolarized for 3 s to voltages of -70 (red), -40 (green), -20 (yellow), 20 (purple), 40 (orange), 70 (blue), and 90 (black) mV. Kv3.4 currents were studied in on-cell patches with 100 mM external KCl.
B. Steady-state currents in patches held at –40 mV. The displayed traces represent 18-second continuous recordings at 6 s per line. (The patches representing expression of Kv3.4 and co-expression of Kv3.4/MiRP2 in CHO cells contain one channel; native C2C12 myocyte patches contain three channels.)

in the SCN4A sodium channel (*53-55*) and in the CACNL1A3 L-type calcium channel (*56*). Based on identification of MiRP2 and its role in a prominent skeletal muscle current, 100 patients with periodic paralysis but no mutations in genes previously associated with the disease were screened for alterations in *KCNE3*. Two pedigrees with a missense mutation (producing an arginine to histidine substitution, R83H, in MiRP2) were thereby identified; the mutation was found only in family members with symptoms, but not in unaffected relatives or control individuals, and resulted in diminished potassium flux, reducing the capacity of the channels to pass current and set resting membrane potential (*13*).

Although *KCNE3* is the first potassium channel gene associated with inherited periodic paralysis, the effects of R83H MiRP2 resemble those of mutations in sodium and calcium channels: membrane depolarization, compromised repolarization, and diminished excitability (*57*). These same effects are seen in acute periodic paralysis caused by barium toxicity, which is thought to result from decreased potassium flux due to channel blockade (*58*). Although periodic paralyses have tended to be grouped together according to clinical findings, the disorders are quite heterogeneous, with overlapping signs, symptoms, and responses to therapy; gene-based classification is now beginning to aid in both diagnosis and treatment strategies (*59, 60*).

MiRP PROMISCUITY

The MiRPs have been demonstrated to interact with multiple α-subunit partners in experimental cells. Whether this promiscuity indicates a versatility of MiRP function in the physiology of potassium channels remains an open question. Whereas MinK assembles with KCNQ1 to form cardiac I_{Ks} currents (*14*), MinK antisense oligonucleotides reduced I_{Kr} currents in murine atrial tumor cells (*61*), thereby suggesting an interaction between MinK and HERG. Indeed, MinK was found to form stable complexes with HERG in CHO and COS cells and to double current density, apparently by increasing the fraction of active channels in the

Kv3.4

MiRP2
+Kv3.4

Figure 9. MiRP2 accelerates inactivation recovery of Kv3.4 channels. Representative low current density on membrane patches from CHO cells expressing Kv3.4 or MiRP2/Kv3.4 cannels during a train of 1-s repetitive pulses to +60 mV from a holding voltage of –80 mV (protocol in inset). Wherease Kv3.4 channels show re-openings at –80 mV following depolarization as they recover slowly from inactivation, MiRP2/Kv3.4 channels recover more quickly and re-openings are not visible.

membrane *(39)*. Consistent with these findings, I_{Kr} currents were diminished in cardiac muscle cells from mice where *Kcne1* was replaced by *lacZ (62)*. Nevertheless, MinK/HERG complexes do not recapitulate the classical properties of I_{Kr} as do MiRP1/HERG complexes, and HERG binds MiRP1 in preference to MinK *(10)*. Conceivably, MinK may assemble with HERG in cells in which MiRP1 is not produced, or may influence MiRP1/HERG complexes to alter their regulation, trafficking, or activity levels.

MiRP1 also exhibits promiscuous interactions. In addition to assembling with HERG to form cardiac I_{Kr} channels *(10)*, it associates with Kv4.2 subunits (which contribute to cardiac and neuronal transient outward currents, I_{to}) to slow channel inactivation and alter the kinetics of 4-aminopyridine blockade *(63, 64)*. Again, it is unclear whether MiRP1/Kv4.2 complexes form in native cells. MiRP1 has also been reported to alter the properties of KCNQ1 when the two subunits are expressed in COS cells *(65)*, although no such effect was seen in two studies using *Xenopus laevis* oocytes *(10, 66)* and one using CHO cells (F. Sesti, personal communication).

MiRP2 appears to enjoy a particularly wide range of interactions. In addition to its assembly with Kv3.4 in native and experimental cells *(13)*, MiRP2 can be expressed along with KCNQ1 in CHO cells to produce a channel that is open at resting membrane potentials, and in oocytes MiRP2 suppresses currents passed by HERG and KCNQ4 α-subunits *(67, 68)*.

Moreover, equivalent positions in MinK and MiRP2 appear to act similarly with their recognized pore-forming partners. Thus, D76N MinK (associated with long QT syndrome) alters KCNQ1 function by shifting activation to positive potentials, reducing single-channel current amplitude, and lowering steady-state open probability; D90N MiRP2 (the analogous mutation) affects Kv3.4 and KCNQ1 in the same ways *(17, 69)*. Similarly, R83H MiRP2 (associated with periodic paralysis) shifts activation to positive

potentials, reduces unitary conductance, and lowers steady-state open probability of complexes with Kv3.4 and KCNQ1, and the equivalent mutation in MinK (K69H) has similar effects on KCNQ1 channels *(69)*. Remarkably, studies with MinK/MiRP2 chimeras and KCNQ1 have revealed that a three-residue stretch in the TM domain (amino acids 57–59 in MinK, 71–73 in MiRP2) is necessary and sufficient to account for contrasting effects of the two peptides on channel activation *(68)*. Although these results suggest that each MiRP combines with different pore-forming partners to produce similar effects, MiRP2 suppresses HERG currents yet increases flux through KCNQ1 and Kv3.4 channels *(13, 67)*.

CONCLUSIONS AND FUTURE DIRECTIONS

The clinical classification, prognosis, and treatment for patients with ion channel defects are often challenging due to overlapping signs and symptoms. Nevertheless, the clear correlations among mutations of *KCNE* genes, patient presentation, and disruption of potassium currents has identified important roles for MiRPs in normal physiology and disease. Thus, patients with long QT syndrome can now be assessed in terms of genotype, in addition to clinical presentation and response to drug therapy, and treatment of patients with periodic paralysis has benefited from the use of genotype as a criterion for therapeutic approach *(70, 60)*.

The multifactorial basis of drug-induced arrhythmia has made the identification of patients at risk for adverse drug reactions rather difficult. Gene-based diagnosis now presents itself as a viable option. Indeed, as the database of allelic variants grows, preprescription genotyping will become a consideration for avoiding drug-induced pathology. Moreover, because MiRP peptides alter the pharmacology of cloned VGK channel α-subunits to recapitulate currents typical of native cells, drug development programs may benefit from study of heteromeric complexes that include both a MiRP and its cognate α-subunit.

The essential role of MiRPs in native channels is evident in congenital disorders arising from *KCNE* mutations. Nevertheless, it is important to note that animal models and human physiology often differ substantially. *Kcne1* knockout (-/-) mice, for example, display loss of MinK, disrupted potassium secretion, degeneration of the inner ear, and profound deafness *(41, 71)*, accurately modeling in these respects patients with JLNS; the mice, however, have only minor changes in cardiovascular function *(62, 72)*.

Review

Thus, action potentials from *Kcne1* (-/-) knockout mice remain normal, whereas long QT syndrome and life-threatening arrhythmia are associated with *KCNE1* missense mutations in humans. Similarly, disruption of *KCNQ1* in mice (encoding the partner for MinK in I_{Ks} formation) results in vestibular deafness but not in electrocardiographic abnormalities *(47)*, although a subsequent report describes conditions similar to JLNS, with both inner ear and cardiac dysfunction *(75)*. Interspecies differences have been attributed to low levels of MinK in adult mice and to the relatively minor role for I_{Kr} and I_{Ks} in cardiac repolarization in newborn animals *(62)*.

Thus far, MinK/KCNQ1, MiRP1/HERG and MiRP2/Kv3.4 are the recognized MiRP/α-subunit partnerships that have been correlated to native currents and disease. However, as MinK and MiRP2 interact with KCNQ1, and MinK, MiRP1, and MiRP2 all interact with HERG, and all three MiRPs enjoy widespread tissue expression, these recognized partnerships may be the tip of the iceberg. Indeed, there is no reason to presume that MiRP interactions are precluded with calcium-activated potassium channels, cyclic–nucleotide gated channels, inward rectifier potassium channels, and even two-P-domain potassium channels. Among many questions that remain to be answered are the rules that govern subunit specificity and whether complexes can contain more than one type of MiRP. As evidenced by their role in health and disease, these diminutive subunits appear to be more powerful than might be expected based on their size. ⬤

References

1. Hille, B. *Ionic Channels of Excitable Membranes* 2nd ed. (Sinauer, Massachusetts, 1992).

2. Sanguinetti, M.C. and Spector, P.S. Potassium channelopathies. *Neuropharmacology* **36**, 755-762 (1997).

3. Jan, L.Y. and Jan,Y.N. Potassium channels and their evolving gates. *Nature* **371**, 119-122 (1994).

4. MacKinnon, R. Determination of the subunit stoichiometry of a voltage-activated potassium channel. *Nature* **350**, 232-235 (1991).

5. Doyle, D.A., Morais Cabral, J., Pfuetzner, R.A., Kuo, A., Gulbis, J.M., Cohen, S.L., Chait, B.T., and MacKinnon, R. The structure of the potassium channel: Molecular basis of K$^+$ conduction and selectivity. *Science* **280**, 69-77 (1998).

6. Sigworth, F.J. Voltage gating of ion channels. *Q. Rev. of Biophys*. **27**, 1-40 (1994).

7. Yellen, G. The moving parts of voltage-gated ion channels. *Q. Rev. Biophys*. **31**, 239-295 (1998).

8. Abbott, G.W. and Goldstein, S.A.N. A superfamily of small potassium channel subunits: Form and function of the MinK-related peptides (MiRPs). *Q. Rev. Biophysics*. **31**, 357-398 (1998).

9. Takumi, T., Ohkubo, H. and Nakanishi, S. Cloning of a membrane protein that induces a slow voltage-gated potassium current. *Science* **242**, 1042-1045 (1988).

10. Abbott, G.W. Sesti, F., Splawski, I., Buck, M., Lehmann, M.H., Timothy, K.W., Keating, M.T., and Goldstein, S.A.N. MiRP1 forms I_{Kr} potassium channels with HERG and is associated with cardiac arrhythmia. *Cell* **97**, 175-187 (1999).

11. Piccini, M., Vitelli, F., Seri, M., Galietta, L.J., Moran, O., Bulfone, A., Banfi , S., Pober, B., and Renieri, A. *KCNE1*-like gene is deleted in AMME contiguous gene syndrome: Identification and characterization of the human and mouse homologs. *Genomics* **60**, 251-257 (1999).

12. Sesti, F., Abbott, G.W., Wei, J., Murray, K.T., Saksena, S., Schwartz, P. J., Priori, S.G., Roden, D.M., George, A.L.J., and Goldstein, S.A.N. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. *Proc. Natl. Acad. Sci. USA* **97**, 10613-10618 (2000).

13. Abbott, G.W., Butler, M.H., Bendahhou, S., Dalakas, M.C., Ptacek, L.J., and Goldstein, S.A.N. MiRP2 forms potassium channels in skeletal muscle with Kv3.4 and is associated with periodic paralysis. *Cell* **104**, 217-231 (2001).

14. Sanguinetti, M.C., Curran, M.E., Zou, A., Shen, J., Spector, P.S., Atkinson, D.L., and Keating, M.T. Coassembly of K(V)Lqt1 and Mink (Isk) proteins to form cardiac I-Ks potassium channel. *Nature* **384**, 80-83 (1996).

15. Busch, A.E., Busch, G.L., Ford, E., Suessbrich, H., Lang, H.J., Greger, R., Kunzelmann, K., Attali, B., and Stuhmer, W. The role of the IsK protein in the specific pharmacological properties of the IKs channel complex. *Br. J. Pharmacol*. **122**, 187-189 (1997).

16. Wollnik, B., Schroeder, B.C., Kubisch, C., Esperer, H.D., Wieacker, P., and Jentsch, T.J. Pathophysiological mechanisms of dominant and recessive KVLQT1 K$^+$ channel mutations found in inherited cardiac arrhythmias. *Hum. Mol. Genet*. **6**, 1943-1949 (1997).

17. Sesti, F. and Goldstein, S.A.N. Single-channel characteristics of wildtype IKs channels and channels formed with two minK mutants that cause long QT syndrome. *J. Gen. Phys*. **112**, 651-664 (1998).

18. Sesti, F., Tai K.K., and Goldstein, S.A.N. MinK endows the IKs potassium channel with sensitivity to internal TEA. *Biophys. J*. **79**, 1369-1378 (2000).

19. Schulze-Bahr, E., Wang, Q., Wedekind, H., Haverkamp, W., Chen, Q., and Sun, Y. *KCNE1* mutations cause Jervell and Lange-Nielsen syndrome. *Nat. Genet*. **17**, 267-268 (1997).

20. Splawski, I., Tristani-Firouzi, M., Lehmann, M.H., Sanguinetti, M.C., and Keating, M.T. Mutations in the hminK gene cause long QT syndrome and suppress IKs function. *Nat. Genet.* **17**, 338-340 (1997).

21. Tyson, J., Tranebjaerg, L., Bellman, S., Wren, C., Taylor, J.F., Bathen, J., Aslaksen, B., Sorland, S.J., Lund, O., Malcolm, S., Pembrey, M., Bhattacharya, S., and Bitner-Glindzicz, M. IsK and KvLQT1: Mutation in either of the two subunits of the slow component of the delayed rectifier potassium channel can cause Jervell and Lange-Nielsen syndrome. *Hum. Mol. Genet.* **6**, 2179-2185 (1997).

22. Swanson, R., Hice, R.E., Folander, K., and Sanguinetti, M.C. The Isk protein, a slowly activating voltage-dependent K⁺ channel. *Semin. Neurosci.* **5**, 117-124 (1993).

23. Kaczmarek, L.K., and Blumenthal, E.M. Properties and regulation of the MinK potassium channel protein. *Physiol. Rev.* **77**, 627-641 (1997).

24. Wang, K.-W., Tai, K.-K., and Goldstein, S.A.N. MinK residues line a potassium channel pore. *Neuron* **16**, 571-577 (1996).

25. Tai, K.K. and Goldstein, S.A.N. The conduction pore of a cardiac potassium channel. *Nature* **391**, 605-608 (1998).

26. Sanguinetti, M.C. and Jurkiewicz, N.K. Two components of cardiac delayed rectifier K⁺ current. Differential sensitivity to block by class III antiarrhythmic agents. *J. Gen. Physio.* **96**, 195-215 (1990).

27. Wang, Q., Curran, M.E., Splawski, I., et al. Positional cloning of a novel potassium channel gene: *KVLQT1* mutations cause cardiac arrhythmias. *Nat. Genet.* **12**, 17-23 (1996).

28. Lesage, F., Attali, B., Lakey, J., Honore, E., Romey, G., Faurobert, E., Lazdunski, M., and Barhanin, J. Are Xenopus oocytes unique in displaying functional IsK channel heterologous expression? *Receptors and Channels* **1**, 143-152 (1993).

29. Pusch, M., Magrassi, R., Wollnik, B., and Conti, F. Activation and inactivation of homomeric KvLQT1 potassium channels. *Biophys. J.* **75**, 785-792 (1998).

30. Yang, Y and Sigworth, F. Single-channel properties of IKs potassium channels. *J. Gen. Physio.* **112**, 665-678 (1998).

31. Goldstein, S.A. and Miller, C. Site-specific mutations in a minimal voltage-dependent K⁺ channel alter ion selectivity and open-channel block. *Neuron.* **7**, 403-408 (1991).

32. Nerbonne, J.M. Molecular basis of functional voltage-gated K⁺ channel diversity in the mammalian myocardium. *J. Physiol.* **525**, 285-298 (2000).

33. Tristani-Firouzi, M., Chen, J., Mitcheson, J.S., and Sanguinetti, M.C. Molecular biology of K⁺ channels and their role in cardiac arrhythmias. *Am. J. Med.* **110**, 50-59 (2001).

34. Goldstein, S.A.N., Bockenhauer, D., O'Kelly, I., and Zilberberg, N. Potassium leak channels with 2 P domains. *Nature Rev. Neurosci.* (in press).

35. Tomaselli, G.F., Beuckelmann, D.J., Calkins, H.G., Berger, R.D., Kessler, P.D., Lawrence, J.H., Kass, D., Feldman, A.M., and Marban, E. Sudden cardiac death in heart failure. The role of abnormal repolarization. *Circulation* **90**, 2534-2539 (1994).

36. Kass, R.S. and Davies, M.P. The roles of ion channels in an inherited heart disease: Molecular genetics of the long QT syndrome. *Cardiovasc. Res.* **32**, 443-454 (1996).

37. Roden, D.M., Lazzara, R., Rosen, M., Schwartz, P.J., Towbin, J., and Vincent, G.M. Multiple mechanisms in the long-QT syndrome — Current knowledge, gaps, and future directions. *Circulation.* **94**, 1996-2012 (1996).

38. Splawski, I., Shen, J., Timothy, K.W., Lehmann, M.H., Priori, S., Robinson, J.L., Moss, A.J., Schwartz, P.J., Towbin, J.A., Vincent, G.M., and Keating, M.T. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. *Circulation* **102**, 1178-1185 (2000).

39. McDonald, T.V., Yu, Z., Ming, Z., Palma, E., Meyers, M.B., Wang, K.W., Goldstein, S.A.N., and Fishman G.I. A MinK-HERG complex regulates the cardiac potassium current IKr. *Nature* **388**, 289-292 (1997).

40. Duggal, P., Vesely, M.R., Wattanasirichaigoon, D., Villafane, J., Kaushik, V., and Beggs, A. H. Mutation of the gene for IsK associated with both Jervell and Lange-Nielsen and Romano-Ward forms of Long-QT syndrome. *Circulation* **97**, 142-146 (1998).

41. Vetter, D.E., Mann, J.R., Wangemann, P., Liu, J., McLaughlin, K.J., Lesage, F., Marcus, D.C., Lazdunski, M., Heinemann, S.F., and Barhanin, J. Inner ear defects induced by null mutation of the isk gene. *Neuron* **17**, 1251-1264 (1996).

42. Smith, P.L., Baukrowitz, T., and Yellen, G. The inward rectification mechanism of the HERG cardiac potassium channel. *Nature* **379**, 833-836 (1996).

43. Sanguinetti, M.C., Jiang, C., Curran, M.E., and Keating, M.T. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. *Cell* **81**, 299-307 (1995).

44. Drici, M.D., Knollmann, B.C., Wang, W.X., and Woosley, R.L. Cardiac actions of erythromycin: Influence of female sex. *JAMA* **280**, 1774-1776 (1998).

45. Minardo, J.D., Heger, J.J., Miles, W.M., Zipes, D.P., and Prystowsky, E.N.

Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy. *N. Engl. J. Med.* **319**, 257-262 (1988).

46. Donger, C., Denjoy, I., Berthet, M., Neyroud, N., Cruaud, C., Bennaceur, M., Chivoret, G., Schwartz, K., Coumel, P., and Guicheney, P. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. *Circulation* **96**, 2778-2781 (1997).

47. Lee, K.L., Jim, M.H., Tang, S.C., and Tai, Y.T. QT prolongation and Torsades de Pointes associated with clarithromycin. *Am. J. Med.* **104**, 395-396 (1998).

48. Witchel, H.J., and Hancox, J.C. Familial and acquired long QT syndrome and the cardiac rapid delayed rectifier potassium current. *Clin. Exp. Pharmacol. Physiol.* **27**, 753-766 (2000).

49. Mitcheson, J.S., Chen, J., Lin, M., Culberson, C., and Sanguinetti, M.C. A structural basis for drug-induced long QT syndrome. *Proc. Nat. Acad. Sci. USA.* **97**, 12329-12333 (2000).

50. Napolitano, C., Schwartz, P.J., Brown, A.M., Ronchetti, E., Bianchi, L., Pinnavia, A., Acquaro, G., and Priori, S. G. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. *J. Cardiovasc. Electrophysiol.* **11**, 691-696 (2000).

51. Wei, J., Yang, I.C., Tapper, A.R., Murray, K.T., Viswanathan, P., Rudy, Y., Bennett, P.B., Norris, K., Balser, J.R., Roden, D.M., and George, A.L.J. KCNE1 polymorphism confers risk of drug-induced long QT syndrome by altering kinetic properties of IKs potassium channels. *Circulation* 495A (1999).

52. Ruppersberg, J.P., Frank, R., Pongs, O., and Stocker, M. Cloned neuronal IK(A) channels reopen during recovery from inactivation. *Nature* **353**, 657-660 (1991).

53. Ptacek, L.J., George Jr., A.L., Griggs, R.C., Tawil, R., Kallen, R.G., Barchi, R.L., Robertson, M., and Leppert, M.F. Identification of a mutation in the gene causing hyperkalemic periodic paralysis. *Cell.* **67**, 1021-1027 (1991).

54. Ptacek, L.J., Trimmer, J.S., Agnew, W.S., Roberts, J.W., Petajan, J.H., and Leppert, M. Paramyotonia congenita and hyperkalemic periodic paralysis map to the same sodium-channel gene locus. *Am. J. Hum. Genet.* **49**, 851-854 (1991).

55. Bulman, D.E., Scoggan, K.A., van Oene, M.D., Nicolle, M.W., Hahn, A.F., Tollar, L.L., and Ebers, G.C. A novel sodium channel mutation in a family with hypokalemic periodic paralysis. *Neurology* **53**, 1932-1936 (1999).

56. Ptacek, L.J., Tawil, R., Griggs, R.C., Engel, A.G., Layzer, R.B., Kwiecinski, H., McManis, P.G., Santiago, L., Moore, M., Fouad, G., and et al. Dihydropyridine receptor mutations cause hypokalemic periodic paralysis. *Cell* **77**, 863-868 (1994).

57. Jurkat-Rott, K., Mitrovic, N., Hang, C., Kouzmekine, A., Iaizzo, P., Herzog, J., Lerche, H., Nicole, S., Vale-Santos, J., Chauveau, D., Fontaine, B., and Lehmann-Horn, F. Voltage-sensor sodium channel mutations cause hypokalemic periodic paralysis type 2 by enhanced inactivation and reduced current. *Proc. Nat. Acad. Sci. USA.* **97**, 9549-9554 (2000).

58. Layzer, R.B. Periodic paralysis and the sodium-potassium pump. *Ann. Neurol.* **11**, 547-552 (1982).

59. Ptacek, L.J. The familial periodic paralyses and nondystrophic myotonias. *Am. J. Med.* **105**, 58-70 (1998).

60. Tawil, R., McDermott, M.P., Brown Jr., R., Shapiro, B.C., Ptacek, L.J., McManis, P.G., Dalakas, M.C., Spector, S.A., Mendell, J.R., Hahn, A.F., and Griggs, R.C. Randomized trials of dichlorphenamide in the periodic

paralyses. Working Group on Periodic Paralysis. *Ann. Neurol.* **47**, 46-53 (2000).

61. Yang, T., Kupershmidt, S., and Roden, D.M. Anti-minK antisense decreases the amplitude of the rapidly activating cardiac delayed rectifier K$^+$ current. *Circ. Res.* **77**, 1246-1253 (1995).

62. Kupershmidt, S., Yang, T., Anderson, M.E., Wessels, A., Niswender, K.D., Magnuson, M.A., and Roden, D.M. Replacement by homologous recombination of the minK gene with lacZ reveals restriction of minK expression to the mouse cardiac conduction system. *Circ. Res.* **84**, 46-52 (1999).

63. Zhang, M., Jiang, M., and Tseng, G-N. MinK-related peptide I associates with Kv4.2 and modulates its gating function: Potential role as b subunit of cardiac transient outward channel? *Circ. Res.* **88**, 1012-1029 (2001).

64. Kim, L.A., Abbott, G.W., Butler, M.H., and Goldstein, S.A.N. A role for MiRP1-Kv4.2 in CNS A-type currents? *Biophys. J.* **80**, 437a (2001).

65. Tinel, N., Diochot, S., Borsotto, M., Lazdunski, M., and Barhanin, J. KCNE2 confers background current characteristics to the cardiac KCNQ1 potassium channel. *EMBO J.* **19**, 6326-6330 (2000).

66. Tapper, A.R. and George, A.L. MinK subdomains that mediate modulation of and association with KvLQT1. *J. Gen. Physiol.* **116**, 379-389 (2000).

67. Schroeder, B.C., Waldegger, S., Fehr, S., Bleich, M., Warth, R., Greger, R., and Jentsch, T.J. A constitutively open potassium channel formed by KCNQ1 and KCNE3. *Nature* **403**, 196-199 (2000).

68. Melman, Y.F., Domenech, A., de la Luna, S., and McDonald, T.V. Structural determinants of KvLQT1 control by the KCNE family of proteins. *J. Biol. Chem.* (in press).

69. Abbott, G.W., and Goldstein, S.A.N. (in preparation).

70. Schwartz, P.J., Priori, S.G., Spazzolini, C., et al. Genotype-phenotype correlation in the long-QT syndrome - Gene-specific triggers for life-threatening arrhythmias. *Circulation* **103**, 89-95 (2001).

71. Letts, V.A., Valenzuela, A., Dunbar, C., Zheng, Q.Y., Johnson, K.R., and Frankel, W.N. A new spontaneous mouse mutation in the *Kcne1* gene. *Mammal. Gen.* **11**, 831-835 (2000).

72. Charpentier, F., Merot, J., Riochet, D., Le Marec, H., and Escande, D. Adult *Kcne1*-knockout mice exhibit a mild cardiac cellular phenotype. *Biochem. Biophys. Res. Commun.* **251**, 806-810 (1998).

73. Wang, K.W. and Goldstein, S.A.N. Subunit composition of minK potassium channels. *Neuron* **14**, 1303-1309 (1995).

74. Barhanin, J., Lesage, F., Guillemare, E., Fink, M., Lazdunski, M., and Romey, G. K(V)LQT1 and IsK (minK) proteins associate to form the I(Ks) cardiac potassium current. *Nature* **384**, 78-80 (1996).

75. Casimiro, M.C., Knollmann, B.C., Ebert, S.N., Vary, J.C. Jr., Greene, A.E., Franz, M.R., Grinberg, A., Huang, S.P., and Pfeifer, K. Targeted disruption of the *Kcnq1* gene produces a mouse model of Jervell and Lange-Nielsen Syndrome. *Proc. Natl. Acad. Sci. USA.* **98,** 2526-2531 (2001).

Geoffrey W. Abbott, Ph.D., is a Postdoctoral Associate in the Section of Developmental Biology and Biophysics and Boyer Center for Molecular Medicine, Yale University. He will soon move to Weill Medical College of Cornell University, Division of Cardiology, as an Assistant Professor of Medicine and Pharmacology. **Steve A. N. Goldstein, M.D., Ph.D., Professor of Pediatrics and Cellular and Molecular Physiology**, is Chief of the Section of Developmental Biology and Biophysics and Faculty Member of the Boyer Center of Molecular Medicine, Yale University. His rabid devotion to ion channels was piqued during postgraduate training with Chris Miller at Brandeis University (1989–1993). He is the recipient of the E. Mead Johnson Award (2001).

Address correspondence to SANG. E-mail steve.goldstein@yale.edu; fax 203-737-2290.